SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Japan's Business Confidence Rises Despite Iran War Uncertainty, BOJ Rate Hike Expected 
Bank of Korea Nominee Shin Hyun-song Calls for Flexible Monetary Policy Amid Iran War Risks 
Oil Prices Surge to Record Monthly Highs as Middle East War Rattles Global Markets 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Oil Prices Hold Near Multi-Year Highs Amid Iran Conflict and Hormuz Supply Fears 
WTO Ministerial Collapse Leaves Global Digital Trade Rules in Limbo 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Canada's Economy Grows Modestly in January 2025, Driven by Energy and Construction 
South Korea's Exports Hit Record High in March on AI-Driven Chip Demand 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
